Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Malignant Lymphoma

  Free Subscription


08.09.2025

1 Am J Hematol
3 Blood
1 BMC Cancer
1 Br J Dermatol
5 Br J Haematol
1 Hum Pathol
2 Int J Cancer
1 Leuk Lymphoma
1 PLoS One
1 Radiother Oncol


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Hematol

  1. ATALLAH-YUNES SA, Nze CC, King RL, Rees MJ, et al
    Multi-Institutional Study of ALK-Positive Large B-Cell Lymphoma: Outcomes in the Era of ALK Inhibitors and Biologically Informed Therapies.
    Am J Hematol. 2025 Sep 3. doi: 10.1002/ajh.70058.
    PubMed         Abstract available


    Blood

  2. HAVRANEK O
    Classic Hodgkin lymphoma: the journey over the destination.
    Blood. 2025;146:1152-1153.
    PubMed        

  3. TATTERTON DJ, Newby ML, Allen JD, Sale BJ, et al
    The Origin, Diagnosis, and Prognosis of Oligomannose-Type Diffuse Large B-Cell Lymphoma.
    Blood. 2025 Sep 2:blood.2025029163. doi: 10.1182/blood.2025029163.
    PubMed         Abstract available

  4. PAL I, Illendula A, Joyner AM, Manavalan JS, et al
    Nanoromidepsin, a Polymer Nanoparticle of the HDAC Inhibitor, Improves Safety and Efficacy in Models of T-cell Lymphoma.
    Blood. 2025 Sep 2:blood.2024027997. doi: 10.1182/blood.2024027997.
    PubMed         Abstract available


    BMC Cancer

  5. JIN J, Ren S, Zhang W, Yang P, et al
    Patient-reported symptom burden and health-related quality of life in patients with aggressive Non-Hodgkin lymphoma: a cross-sectional study.
    BMC Cancer. 2025;25:1406.
    PubMed         Abstract available


    Br J Dermatol

  6. GHOSH S, Pavlova O, Latshaw A, Kim D, et al
    Multi-Harmonic Imaging-Based Automated Recognition of Cutaneous T-Cell Lymphoma.
    Br J Dermatol. 2025 Sep 4:ljaf345. doi: 10.1093.
    PubMed         Abstract available


    Br J Haematol

  7. LUMINARI S, Barbieri E, Nizzoli ME
    Towards a chemo-free approach for follicular lymphoma.
    Br J Haematol. 2025 Aug 30. doi: 10.1111/bjh.70126.
    PubMed         Abstract available

  8. KLEINSTERN G, Robinson DP, Abu Seir R, Perlman R, et al
    European-based polygenic risk score and genome-wide association study of B-cell non-Hodgkin lymphoma subtypes in Israeli Jews and Palestinian Arabs.
    Br J Haematol. 2025 Aug 31. doi: 10.1111/bjh.70125.
    PubMed         Abstract available

  9. MARIOTTI J, Pinton C, Giordano L, Taurino D, et al
    Reduced incidence of relapse after checkpoint inhibitors relative to brentuximab vedotin as salvage therapy before allogeneic stem cell transplantation for refractory/relapsed Hodgkin lymphoma: A retrospective analysis.
    Br J Haematol. 2025 Aug 31. doi: 10.1111/bjh.70091.
    PubMed         Abstract available

  10. SONG Y, Zou D, Yang H, Wu J, et al
    Two-year follow-up of relmacabtagene autoleucel in relapsed or refractory follicular lymphoma in RELIANCE study.
    Br J Haematol. 2025 Sep 1. doi: 10.1111/bjh.20122.
    PubMed         Abstract available

  11. CHAGANTI S, Dulobdas V, Wilson MR, Tucker D, et al
    Clinical management of bispecific antibody therapy for lymphoma: A British Society for Haematology Good Practice Paper.
    Br J Haematol. 2025 Sep 5. doi: 10.1111/bjh.70018.
    PubMed        


    Hum Pathol

  12. KIM B, Chae SW, Kim HJ, Roh J, et al
    Comparative analysis of the tumor microenvironment in primary CNS and testicular large B-cell lymphomas using digital image analysis and its implications for immunotherapy.
    Hum Pathol. 2025;163:105874.
    PubMed         Abstract available


    Int J Cancer

  13. MOORE A, Kane E, Teras LR, Machiela MJ, et al
    Genetically determined body mass index is associated with diffuse large B-cell lymphoma in polygenic and Mendelian randomization analyses.
    Int J Cancer. 2025 Sep 5. doi: 10.1002/ijc.70039.
    PubMed         Abstract available

  14. BARNA G, Szaloki G, Mark A, Hunyadi A, et al
    CD86, the double agent: Significance of CD86 expression in B-cell malignancies.
    Int J Cancer. 2025;157:1772-1780.
    PubMed         Abstract available


    Leuk Lymphoma

  15. SHAH B, Challagulla S, Xu S, Williams R, et al
    Zanubrutinib versus acalabrutinib indirect treatment comparison in relapsed or refractory mantle cell lymphoma.
    Leuk Lymphoma. 2025 Sep 1:1-11. doi: 10.1080/10428194.2025.2541911.
    PubMed         Abstract available


    PLoS One

  16. THEIL DE, Butow C, Scharf S, Schafer H, et al
    Behavioral investigation of reactive and neoplastic lymphocytes in human lymph nodes in 4D.
    PLoS One. 2025;20:e0331439.
    PubMed         Abstract available


    Radiother Oncol

  17. BOERSMA LJ, Hessels A, Roberti S, Seravall E, et al
    Selection of patients for proton therapy to reduce risk of second primary lung and breast cancer.
    Radiother Oncol. 2025 Jul 4:110998. doi: 10.1016/j.radonc.2025.110998.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.